In an adequately powered, randomized controlled trial conducted over 2 years, the desired clinical outcome (i.e. prevention of a serious cardiovascular event) with a new drug is achieved in 25% of the study sample. In the patients who receive a placebo, only 15% obtain the same clinical benefit. The relative risk reduction achieved with the new drug over the study period is:
Tambra
1 months agoAltha
1 months agoJamal
1 months agoPamella
4 days agoXenia
8 days agoSkye
18 days agoDeonna
19 days agoElvis
1 months agoDenise
10 days agoJaclyn
12 days agoTimothy
29 days agoYuonne
2 months agoMalcolm
14 days agoKizzy
25 days agoAndrew
1 months agoOmega
1 months agoThea
1 months agoMelynda
2 months agoEllen
2 months agoDaren
2 months agoRuth
2 months ago